Publications by authors named "Timothy P Rolph"

Claim this Profile
N
Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin.
Adam S Kinne, Erik J Tillman, Sanofar J Abdeen, Derrick E Johnson, Elijah S Parmer, Timothy P Rolph

J Pharm Biomed Anal· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial.
Stephen A Harrison, Peter J Ruane, Bradley L Freilich, Guy Neff, Rashmee Patil, Timothy P Rolph

Nat Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Muscle-Liver Trafficking of BCAA-Derived Nitrogen Underlies Obesity-Related Glycine Depletion.
Phillip J White, Amanda L Lapworth, Robert W McGarrah, Lydia Coulter Kwee, Scott B Crown, Timothy P Rolph

Cell Rep· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human sebum requires de novo lipogenesis, which is increased in acne vulgaris and suppressed by acetyl-CoA carboxylase inhibition.
William P Esler, Gregory J Tesz, Marc K Hellerstein, Carine Beysen, Raja Sivamani, Timothy P Rolph

Sci Transl Med· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates.
Albert M Kim, Veena R Somayaji, Jennifer Q Dong, Timothy P Rolph, Yan Weng

Diabetes Obes Metab· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism.
Kay Ahn, Markus Boehm, Matthew F Brown, Jessica Calloway, Ye Che, Timothy P Rolph

ACS Chem Biol· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export.
Phillip J White, Amanda L Lapworth, Jie An, Liping Wang, Robert W McGarrah, Timothy P Rolph

Mol Metab· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.
Saswata Talukdar, Yingjiang Zhou, Dongmei Li, Michelle Rossulek, Jennifer Dong, Timothy P Rolph

Cell Metab· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Acetyl Group Buffering Action of Carnitine Acetyltransferase Offsets Macronutrient-Induced Lysine Acetylation of Mitochondrial Proteins.
Michael N Davies, Lilja Kjalarsdottir, J Will Thompson, Laura G Dubois, Robert D Stevens, Timothy P Rolph

Cell Rep· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of combined resistance and aerobic exercise training on branched-chain amino acid turnover, glycine metabolism and insulin sensitivity in overweight humans.
Erin L Glynn, Lucy W Piner, Kim M Huffman, Cris A Slentz, Lorraine Elliot-Penry, Timothy P Rolph

Diabetologia· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isocitrate-to-SENP1 signaling amplifies insulin secretion and rescues dysfunctional β cells.
Mourad Ferdaoussi, Xiaoqing Dai, Mette V Jensen, Runsheng Wang, Brett S Peterson, Timothy P Rolph

J Clin Invest· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance.
Barbara Bernardo, Min Lu, Gautam Bandyopadhyay, Pingping Li, Yingjiang Zhou, Timothy P Rolph

Sci Rep· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.
Derek M Erion, Amanda Lapworth, Paul A Amor, Guoyun Bai, Nicholas B Vera, Timothy P Rolph

PLoS One· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Jeffrey A Pfefferkorn, Angel Guzman-Perez, John Litchfield, Robert Aiello, Judith L Treadway, Timothy P Rolph

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis